NCT07203001View on ClinicalTrials.gov

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 11, 2025

Primary Completion Date

May 2, 2029

Study Completion Date

May 2, 2029

Conditions
Still´s Disease
Interventions
DRUG

MAS825

Experimental drug

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY